Phio Pharmaceuticals Corp. (PHIO) Stock Ticker
Market factors today
Unlock the full PHIO picture
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
PHIO stock facts
| Ticker symbol | PHIO |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $11.7M |
| CEO | Robert L. Bitterman |
| Employees | 6 |
| Headquarters | King of Prussia, PA, US |
| IPO date | 2012-05-10 |
| Website | www.phiopharma.com |
What you can see for PHIO on Tickr
Live PHIO price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the PHIO report.
Rankings
FAQ
What is the ticker symbol for Phio Pharmaceuticals Corp.?
The ticker symbol for Phio Pharmaceuticals Corp. is PHIO, listed on the NASDAQ.
What is PHIO?
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene…